Utility of tau biomarkers for detecting clinical outcomes in preclinical Alzheimer's disease

Abstract

Background: While amyloid‐β pathology is a hallmark of preclinical Alzheimer's disease (AD), tau pathology is a key biomarker for early disease‐modifying interventions due to its strong prognostic association with cortical atrophy and cognitive decline.